Re: Alexander D. Sherry, Van To, Criselle D’souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. 2026;90:13–18
Re: Alexander D. Sherry, Van To, Criselle D’souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. 2026;90:13–18. // European Urology. – URL: https://www.sciencedirect.com/science/article/pii/S0302283826022372?dgcid=rss_sd_all
Re: Alexander D. Sherry, Van To, Criselle D’souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. 2026;90:13–18. European Urology. https://www.sciencedirect.com/science/article/pii/S0302283826022372?dgcid=rss_sd_all
“Re: Alexander D. Sherry, Van To, Criselle D’souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. 2026;90:13–18.” European Urology.
@article{article45450,
title = {Re: Alexander D. Sherry, Van To, Criselle D’souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. 2026;90:13–18},
journal = {European Urology},
url = {https://www.sciencedirect.com/science/article/pii/S0302283826022372?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...